Biogen to Present 96-Week Data From Diranersen Alzheimer’s Trial at CTAD 2026
Bitget2026/10/29 11:00- Biogen will present new Alzheimer’s disease study data at CTAD in Boston, November 16-19, 2026.
- Investigational diranersen’s Phase 2 CELIA update will cover longer-term efficacy, safety and biomarkers, building on results presented in July 2026.
- Leqembi presentations will examine five-year treatment outcomes and safety, alongside three-year real-world evidence on maintenance therapy and at-home subcutaneous administration.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
Crypto prices
More
